MAXCLARITY II (2.5% BPO) Foam Treatment
Sponsors
Stiefel, a GSK Company
Conditions
Acne Vulgaris
Phase 4
U0289-401: Eight Week, Split-face, Study to Determine and Compare the Efficacy and Tolerability of MAXCLARITY™ II to PROACTIV™
CompletedNCT01706250
Start: 2009-09-01End: 2010-01-25Updated: 2017-08-23
U0289-402: An Open Label, 8 Week Study to Evaluate the Efficacy and Tolerability of MAXCLARITY II in Subjects With Acne
CompletedNCT01706263
Start: 2009-08-01End: 2009-11-20Updated: 2018-01-08
8 Week Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITY II and MURAD To Treat Acne
CompletedNCT02524665
Start: 2009-09-30End: 2009-12-31Updated: 2017-04-13